S
Susan E. Andrade
Researcher at University of Massachusetts Medical School
Publications - 132
Citations - 11022
Susan E. Andrade is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 51, co-authored 129 publications receiving 10129 citations. Previous affiliations of Susan E. Andrade include Harvard University & Regions Hospital.
Papers
More filters
Journal ArticleDOI
Methods for evaluation of medication adherence and persistence using automated databases.
TL;DR: The aim was to perform a systematic review of the methods currently being used to assess adherence and persistence in pharmacoepidemiological and pharmacoeconomic studies using automated databases.
Journal ArticleDOI
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
David J. Graham,Judy A. Staffa,Deborah Shatin,Susan E. Andrade,Stephanie D. Schech,Lois La Grenade,Jerry H. Gurwitz,K. Arnold Chan,Michael J. Goodman,Richard Platt +9 more
TL;DR: Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastsatin, and simvastsatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus.
Journal ArticleDOI
Comparison of drug adherence rates among patients with seven different medical conditions.
TL;DR: To compare drug adherence rates among patients with gout, hypercholesterolemia, hypertension, hypothyroidism, osteoporosis, seizure disorders, and type 2 diabetes mellitus by using a standardized approach.
Journal ArticleDOI
Prescription drug use in pregnancy.
Susan E. Andrade,Jerry H. Gurwitz,Robert L. Davis,K. Arnold Chan,Jonathan A. Finkelstein,Kris K. Fortman,Heather McPhillips,Marsha A. Raebel,Douglas W. Roblin,David H. Smith,Marianne Ulcickas Yood,Abraham N. Morse,Richard Platt +12 more
TL;DR: The finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.
Journal ArticleDOI
Discontinuation of antihyperlipidemic drugs : do rates reported in clinical trials reflect rates in primary care settings ?
Susan E. Andrade,Alexander M. Walker,Lawrence K. Gottlieb,Norman K. Hollenberg,Marcia A. Testa,Gordon M. Saperia,Richard Platt +6 more
TL;DR: The effectiveness and tolerability of antihyperlipidemic medications should be studied further in populations that typically use the agents, and in open-label studies were similar to those in the HMOs.